Arcadia Biosciences, the VC-backed agtech firm that is planning an initial public offering on the Nasdaq, has hired Thomas O’Neil as chief financial officer.
O’Neil joins from Sorbent Therapeutics, a private biopharmaceutical company, but brings experience of the US listed market as he previously worked in finance at Monogram Biosciences, which listed on the Nasdaq in 2000. He has also worked at ChemGenex Pharmaceuticals, a publicly-traded Australian company, and biotechnology firms Nodality and HX Diagnostics.
“Mr. O’Neil’s experience includes initial public offerings, oversight and management of equity and debt financings, mergers and acquisitions, collaborations and investor relations,” reads the press release.
“Tom has a strong track record of driving growth in life sciences businesses and brings a broad set of skills that will expand the capabilities and capacity of our finance and management teams,” said Eric Rey, president and chief executive of Arcadia Biosciences in a statement.
Arcadia Biosciences focuses on developing agricultural products that benefit the environment and enhance human health.
The company filed for an $86.25 million IPO last month and hired JPMorgan and Credit Suisse as joint lead book-running managers with Piper Jaffray & Co as additional book-running manager, according to SEC filings.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: